Medicines Discovery Catapult

PACE - Addressing the global threat of Antimicrobial Resistance. MDC, Innovate UK and LifeArc joined forces to create PACE-AMR (Pathways to Antimicrobial Clinical Efficacy), a £30m initiative supporting early-stage innovation against antimicrobial resistance (AMR) to save lives. Launched in October 2023, PACE aims to support early-stage innovation in AMR, driving the development of new tests and treatments to tackle deadly infections. Follow PACE-AMR Visit https://hubs.li/Q02MkThH0 #AntimicrobialResistance #AMR

NPIP - Patients benefit from game-changing full-body scans to provide a richer picture of human health for clinical research. The UK’s first-of-its-kind national total-body positron emission tomography (PET) imaging platform (NPIP) for drug discovery was launched in partnership between MDC, the Medical Research Council (MRC) and Innovate UK in October 2023. Total-body PET can provide a holistic view of an individual’s body to enable a greater understanding of multi-organ, complex disease progression. Follow NPIP Visit https://hubs.li/Q02MkTgT0 #TotalBodyPET #NuclearMedicines #Radiotracers #Research Medical Research Council | Innovate UK

CF AMR Syndicate - Meeting unmet patient needs through collaboration. The CF AMR Syndicate continues to support innovators through the provision of samples from the UK Cystic Fibrosis Infection Biorepository and via the publication of Diagnostic Target Product Profiles (TPPs). It has engaged the community by delivering key events and continues to grow its network and knowledge exchange reach, with over 200 members. Follow CF AMR Syndicate Visit https://hubs.li/Q02MkSp10 LifeArc | Cystic Fibrosis Trust

MDC, developing and running national research and development programmes. Join us this week as we spotlight our national programme portfolio. #ResearchAndDevelopment #UKLifeSciences #AMR #CysticFibrosis #TotalBodyPET #Psychiatry #Nanomedicines

Dr. Juliana Maynard, Head of Translational Imaging at Medicines Discovery Catapult and Director of Operations and Engagement at the National PET Imaging Platform, highlights the revolutionary impact of total-body PET technology. NPIP 👉 Read more https://lnkd.in/ehjaH4QD #MedicalImaging #TotalBodyPET #HealthcareInnovation #PatientCare #

We are delighted to be attending British Society for Nanomedicine Annual Meeting 2024, which takes place on 9-10 September at University of Cambridge. Join us, alongside other industry leading scientists, to explore the latest research and build networks that will underpin future translation. 📌💊 👇 Click the link below to learn more: https://hubs.li/Q02M0pjY0 #BSNM #Nanomedicine #Event #ComplexMedicines Sarah Brockbank | Lorna FitzPatrick

📢 MDC Lead Scientist Benedetta Arno (benedetta arnò) will be speaking at the 'Innovations in Radiopharmaceuticals' Symposium on 17 September. ▶ Benedetta's talk is 'Translational Research in #Radiopharmaceutical Development: An Industry Perspective in Navigating the Frontiers of Therapeutic Innovation'. Details are in the post below 👇 Champions Oncology, Inc. #Oncology #CancerTreatment #LifeSciences #Research Juliana Maynard | Lynne Braidwood

🖥️ Available for Catch Up | MDC Connects Webinar Series Episode 1, creating a richer national R&D pipeline, the therapeutic funding and tackling the challenges together. MDC Connects: Insight from experts from the drug discovery community Watch now: https://hubs.li/Q02Lg8cY0

▶️Blog: Dr Andrzej Rutkowski, Lead Scientist at MDC, Greatly Enhancing the Capacity for Rapid and Comprehensive Mutation Detection. Detecting tumour DNA through liquid biopsies marks the new frontier in oncology, providing a wealth of critical data for drug development research. Read the full blog here: https://hubs.li/Q02KrtKL0 #DrugDiscovery #LifeSciences

We have recently updated the resources page on our website. Here you can find information on our latest news, videos, blogs, and more. 🔗 Stay updated and explore here: https://hubs.li/Q02K4GcM0 #MDC #LifeSciences #DrugDiscovery